Inflammatory Bowel Disease

In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that although some concerns remain for switching patients between interchangeable biosimilars, data has continued to show acceptable outcomes as well as “increased access.”

If you see more than a few patients with inflammatory bowel disease, you likely already have been asked by a third-party payer to switch a patient’s adalimumab prescription from the reference product to a biosimilar.

The age of biosimilars has come for gastroenterology. This includes interchangeable products, three of which are now on the market. How this will impact patient care in the near and distant future is the subject of much speculation.

Induction and maintenance treatment with infliximab was more efficacious than vedolizumab in patients with Crohn’s disease, while efficacy was similar between the two therapies in patients with ulcerative colitis, according to data.

Female sex, smoking, Crohn’s disease and a history of surgery to treat inflammatory bowel disease were associated with an increased risk for developing extraintestinal manifestations of disease, according to research in Gastroenterology.

Once-daily Rinvoq 45 mg provided “rapid relief” of stool frequency and abdominal pain score within the first week of induction therapy in patients with moderately to severely active Crohn’s disease, according to a data analysis.

Early treatment with infliximab plus an immunomodulator resulted in more frequent steroid-free and surgery-free remission at 1 year compared with conventional therapy among patients with newly diagnosed Crohn’s disease, researchers reported.

In a Healio video exclusive, Sneha Dave, recaps a roundtable series presented by the Crohn’s and Colitis Young Adults Network, which encourages young adults with inflammatory bowel disease to discuss gaps and opportunities in research.

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses data he presented at the GUILD Conference, which show patients with inflammatory bowel disease are at increased risk for cardiovascular events, likely driven by inflammation.

A 12-point plan from the AGA proposed ways in which collaboration between the health care community, insurers, pharmaceutical companies and legislators can improve “fixable problems” affecting patients with inflammatory bowel disease.